论文部分内容阅读
4-[2-(5-氯-2-甲氧-苯甲酰胺)-乙基]-苯甲酸HB-699可强烈刺激胰岛素的释放,它是一种没有磺脲类降糖药化学结构的新药。用胶原酶(collagenase)分离的小鼠胰岛,HB-699 10μg/ml在葡萄糖100～200mg%时增加胰岛素释放,同时有胰岛素或胰岛素原的生物合成(~3H-亮氨酸结合)减低,这与磺脲的作用类似。用分离小鼠的胰岛作剂量反应研究证明,最小有效浓度在10～50μg/ml。体外大致等强分泌作用所需的量,为优降糖的5～10倍。HB-699与优降糖合用并不增加效果。除去钙离子则可减低由HB-699所引起的胰岛素排出量。在注意寻找HB-699和磺脲在作用方式方面的差异时,特别有趣的是HB-699刺激胰岛素释放也在没有葡萄糖存在的情况下产生。
HB-699 strongly stimulates the release of insulin, a chemical that does not possess the sulfonylurea hypoglycemic agent New medicine In mouse islets isolated with collagenase, HB-699 10 μg / ml increases insulin release at 100-200 mg% of glucose with a decrease in insulin or pro-insulin biosynthesis (~ 3H-leucine binding), which Similar effect with sulfonylurea. Dose mice with islet for dose-response studies have shown that the minimum effective concentration of 10 ~ 50μg / ml. Approximately strong in vitro secretion required for the amount of glyburide 5 to 10 times. HB-699 combined with glyburide does not increase the effect. Removal of calcium ions reduces the amount of insulin excreted by HB-699. Of particular interest when looking at the differences in the mode of action of HB-699 and sulfonylureas is that HB-699 stimulates insulin release also in the absence of glucose.